Efficacy Of Sorafenib In Combination With Gemcitabine And Fluorouracil In Metastatic Renal-Cell Carcinoma: Preliminary Result Of A Multicenter Phase Ii Study.
Jun Guo,Chuan Liang Cui,H. Chen,Xiaodong Xie,Jianhua Chen,Jun Liang,F. Li,T. S. Liu,Zhihong Chi,Lu Si,Xi Nan Sheng,Siming Li
DOI: https://doi.org/10.1200/jco.2011.29.15_suppl.e15042
IF: 45.3
2011-01-01
Journal of Clinical Oncology
Abstract:e15042 Background: To investigate the efficacy in terms of the overall response rate and progression-free survival (PFS) time of the combination of gemcitabine, fluorouracil, and sorafenib for metastatic renal cell carcinoma (RCC) in a multicenter phase II clinical trial. Methods: Patients were enrolled at seven centers across China between November 2008 and April 2010. Patients were aged 18 years or older, had confirmed metastatic RCC with clear-cell histology, had an Eastern Cooperative Oncology Group performance status of 0 or 1, and had not undergone previous therapy. Treatment consisted of intravenous gemcitabine 800 mg/m2 (days 1,15), fluorouracil 1250 mg/m2 civ 48h (days 1,15), Q28d, and oral sorafenib 400 mg twice a day (days 1-28), for four cycles, followed by sorafenib monotherapy. The primary endpoint was median PFS analyzed in a population of all patients who received treatment. Results: Fifty-four patients enrolled in the study, and 52 received treatment. Median age was 54.18±11.57, with MSKCC status of 0-2. The 6-month PFS rate has reached 56.25%; however, the median PFS was not reached. Partial response or stable disease were achieved in 23 patients (44%) and 28 patients (54%), respectively, with a disease control rate was 98%. The effect of dose escalation of sorafenib remained evident in patients with disease progression. Most adverse events were grade 1 or 2, and included hand-foot skin reaction (n=32), rash (n=24), diarrhea (n=23), fatigue (n=13), and hypertension (n=4). Grade 3 adverse events included hand-foot skin reaction in 8, thrombocytopenia in 1, and neutropenia in 13 patients. One patient terminated treatment prematurely due to pulmonary edema possibly related to study drug. Conclusions: Improved response rates and PFS were achieved with the regimen of sorafenib in combination with gemcitabine and fluorouracil as compared to that was observed after sorafenib monotherapy in patients with metastatic RCC. In addition, the combination was well tolerated. Longer follow-up is needed, and further investigation preferably in a randomized trial may be warranted.